BR9813642A - "derivados de isoquinolina substituìdos e seu uso como anticonvulsivos" - Google Patents

"derivados de isoquinolina substituìdos e seu uso como anticonvulsivos"

Info

Publication number
BR9813642A
BR9813642A BR9813642-9A BR9813642A BR9813642A BR 9813642 A BR9813642 A BR 9813642A BR 9813642 A BR9813642 A BR 9813642A BR 9813642 A BR9813642 A BR 9813642A
Authority
BR
Brazil
Prior art keywords
alkyl
cycloalkyl
disorders
hydrogen
alkenyl
Prior art date
Application number
BR9813642-9A
Other languages
English (en)
Inventor
Steven Coulton
Roderick Alan Porter
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BR9813642A publication Critical patent/BR9813642A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE ISOQUINOLINA SUBSTITUìDOS E SEU USO COMO ANTICONVULSIVOS" Composto da fórmula (I) ou sal ou solvato seu farmaceuticamente aceitável, em que Q é um anel heteroarílico ou arílico monocíclico ou bicíclico, R¹ é hidrogênio, alquila C~ 1-6~ (opcionalmente substituído por hidróxi ou alcóxi C~ 1-4~), alquenila C~ 1-6~, alquinila C~ 1-6~, alquila C~ 1-6~CO-, formila, CF~ 3~CO- ou alquila C~ 1-6~SO~ 2~-, R² é hidrogênio ou até três substituintes selecionados dentre halogênio, NO~ 2~, CN, N~ 3~, CF~ 3~O-, CF~ 3~S-, CF~ 3~CO-, triflúoro metil diazirinila, alquila C~ 1-6~, alquenila C~ 1-6~, alquinila C~ 1-6~, perflúoro alquila C~ 1-6~, cicloalquila C~ 3-6~, cicloalquila C~ 3-6~- alquila C~ 1-4~-, alquila C~ 1-6~O-, alquila C~ 1-6~CO-, cicloalquila C~ 3-6~O-, cicloalquila C~ 3-6~CO-, cicloalquila C~ 3-6~- alquila C~ 1-4~O-, cicloalquila C~ 3-6~-alquila C~ 1-4~ CO-, fenila, fenóxi, benzilóxi, benzoíla, fenil-alquila C~ 1-4~-, alquila C~ 1-6~S-, alquila C~ 1-6~SO~ 2~, (alquila C~ 1-4~)~ 2~NSO~ 2~-, (alquila C~ 1-4~)NHSO~ 2~-, (alquila C~ 1-4~)~ 2~NCO-, (alquila C~ 1-4~)NHCO, CONH~ 2~, CF~ 3~SO~ 2~, alquenila C~ 1-6~, alquinila C~ 1-6~ ou hidróxi-alquila C~ 1-6~; ou -NR³R^ 4^ em que R³ é hidrogênio ou alquila C~ 1-4~, e R^ 4^ é hidrogênio, alquila C~ 1-4~, formila, -CO~ 2~ alquila C~ 1-4~ ou -COalquila C~ 1-4~; ou dois grupamentos R² juntos formam um anel carbocíclico que é saturado ou insaturado e não substituído ou substituído por -OH ou =O; e X é halogênio, alcóxi C~ 1-6~, C~ 1-6~ alquila, alquenila C~ 2-6~ opcionalmente substituído por fenila; são úteis no tratamento e/ou profilaxia de ansiedade, mania, depressão, distúrbios do pânico e/ou agressão, distúrbios associados uma hemorragia subaracnóide ou choque neural, dos efeitos associados com privação de substâncias de uso abusivo tais como cocaína, nicotina, álcool e benzodiazepinas, de distúrbios que podem ser tratados e/ou prevenidos com agentes anticonvulsivos tais como epilepsia, inclusive epilepsia pós-traumática, doença de Parkinson, psicose, enxaqueca, isquemia cerebral, doença de Alzheimer e outras doenças degenerativas tais como coréia de Huntingdon, esquizofrenia, distúrbios compulsivos obsessivos (OCD), deficiência neurológica associada com AIDS, distúrbios do sono (inclusive distúrbios do ritmo circadiano, e narcolepsia), tiques (tal como o síndrome de Giles de la Tourette), lesão cerebral traumática, tinnitus, nevralgia, especialmente nevralgia trigeminal, nevralgia, dor neuropática, dor dental, dores do câncer, atividade neuronal inadequada resultando em neurodistesias em doenças tais como diabetes, esclerose múltipla (MS) e doença dos neurónios motores, ataxias, rigidez muscular (espasticidade), disfunção da articulação temporomandibular, e esclerose lateral amiotrófica (ALS).
BR9813642-9A 1997-12-17 1998-12-16 "derivados de isoquinolina substituìdos e seu uso como anticonvulsivos" BR9813642A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9726695.1A GB9726695D0 (en) 1997-12-17 1997-12-17 Novel compounds
PCT/GB1998/003785 WO1999031068A1 (en) 1997-12-17 1998-12-16 Substituted isoquinoline derivatives and their use as anticonvulsants

Publications (1)

Publication Number Publication Date
BR9813642A true BR9813642A (pt) 2000-10-17

Family

ID=10823780

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9813642-9A BR9813642A (pt) 1997-12-17 1998-12-16 "derivados de isoquinolina substituìdos e seu uso como anticonvulsivos"

Country Status (30)

Country Link
US (1) US6248754B1 (pt)
EP (1) EP1042296B1 (pt)
JP (1) JP2002508360A (pt)
KR (1) KR20010033194A (pt)
CN (1) CN1125052C (pt)
AP (1) AP2000001832A0 (pt)
AR (1) AR014942A1 (pt)
AT (1) ATE260258T1 (pt)
AU (1) AU744451B2 (pt)
BG (1) BG104607A (pt)
BR (1) BR9813642A (pt)
CA (1) CA2315079A1 (pt)
CO (1) CO5080731A1 (pt)
DE (1) DE69821988T2 (pt)
EA (1) EA200000657A1 (pt)
ES (1) ES2216333T3 (pt)
GB (1) GB9726695D0 (pt)
HU (2) HUP0000987A3 (pt)
ID (1) ID24810A (pt)
IL (1) IL136382A0 (pt)
MA (1) MA26583A1 (pt)
NO (1) NO315649B1 (pt)
NZ (1) NZ504706A (pt)
OA (1) OA11526A (pt)
PE (1) PE20000006A1 (pt)
PL (1) PL341222A1 (pt)
SK (1) SK9142000A3 (pt)
TR (1) TR200001791T2 (pt)
WO (1) WO1999031068A1 (pt)
ZA (1) ZA9811503B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010016657A1 (en) * 1997-03-18 2001-08-23 Smithkline Beecham P.L.C. Substituted isoquinoline derivatives and their use as anticonvulsants
WO1999016752A1 (en) * 1997-09-30 1999-04-08 Molecular Designs International, Inc. β3-ADRENORECEPTOR AGONISTS, AGONIST COMPOSITIONS AND METHODS OF USING
GB9915589D0 (en) * 1999-07-02 1999-09-01 Smithkline Beecham Plc Novel compounds
AU1734401A (en) * 1999-12-09 2001-06-18 Mitsubishi Pharma Corporation Carboxyamido derivatives
US6593341B2 (en) 2001-03-29 2003-07-15 Molecular Design International, Inc. β3-adrenoreceptor agonists, agonist compositions and methods of making and using the same
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US6596734B1 (en) 2002-10-11 2003-07-22 Molecular Design International, Inc. Tetrahydroisoquinoline compounds for use as β3-adrenoreceptor agonists
US7119214B2 (en) * 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
GB0619176D0 (en) * 2006-09-29 2006-11-08 Lectus Therapeutics Ltd Ion channel modulators & uses thereof
TWI459947B (zh) 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022900A (en) * 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
PL330465A1 (en) * 1996-06-17 1999-05-24 Smithkline Beecham Plc Substituted benzamide derivatives and their application as anticonvulsants
BR9809047A (pt) * 1997-03-18 2000-08-01 Smithkline Beecham Plc Derivados de isoquinolina substituìda e o uso dos mesmos como anticonvulsivantes

Also Published As

Publication number Publication date
NO315649B1 (no) 2003-10-06
NO20003142L (no) 2000-06-16
AU1572499A (en) 1999-07-05
EP1042296B1 (en) 2004-02-25
CN1284946A (zh) 2001-02-21
OA11526A (en) 2004-02-09
CA2315079A1 (en) 1999-06-24
CN1125052C (zh) 2003-10-22
TR200001791T2 (tr) 2000-12-21
PE20000006A1 (es) 2000-03-01
KR20010033194A (ko) 2001-04-25
ZA9811503B (en) 2000-06-15
SK9142000A3 (en) 2000-11-07
EP1042296A1 (en) 2000-10-11
DE69821988D1 (de) 2004-04-01
BG104607A (bg) 2001-02-28
HUP0000987A2 (hu) 2000-09-28
NO20003142D0 (no) 2000-06-16
AR014942A1 (es) 2001-04-11
JP2002508360A (ja) 2002-03-19
PL341222A1 (en) 2001-03-26
GB9726695D0 (en) 1998-02-18
AU744451B2 (en) 2002-02-21
HUP0000987A3 (en) 2000-10-30
HUP0004663A3 (en) 2002-10-28
IL136382A0 (en) 2001-06-14
ATE260258T1 (de) 2004-03-15
MA26583A1 (fr) 2004-12-20
DE69821988T2 (de) 2005-01-05
EA200000657A1 (ru) 2000-12-25
NZ504706A (en) 2002-11-26
AP2000001832A0 (en) 2000-06-30
HUP0004663A2 (hu) 2001-05-28
ES2216333T3 (es) 2004-10-16
WO1999031068A1 (en) 1999-06-24
US6248754B1 (en) 2001-06-19
ID24810A (id) 2000-08-24
CO5080731A1 (es) 2001-09-25

Similar Documents

Publication Publication Date Title
BR9813642A (pt) "derivados de isoquinolina substituìdos e seu uso como anticonvulsivos"
ES2135707T3 (es) Analogos de la benzamida, utiles como inhibidores de la enzima parp (adp-ribosiltransferasa, adprt) de reparacion del adn.
BR9808254A (pt) Compostos, uso e processo para a preparação dos mesmos, composição farmacêutica, e, processo para tratamento da depressão, ansiedade, doença de parkinson, obesidade, desordens cognitivas, doenças repentinas, desordens neurológicas e de neuroproteção para proteger contra condições tais como derrame cerebral em seres humanos.
CA2146007A1 (en) Substituted Quinuclidines
BR9507561A (pt) Ligação de E-selectina P-selectina ou L-selectina para sialil-lewis X ou sialil-lewis A
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
CA2284732A1 (en) Analogs of cocaine
NO960380L (no) Middel til behandling av neurosykdommer
CA2339661A1 (en) Use of derivatives of aryl(or heteroaryl)azolylcarbinols in the manufacture of a medicament for the treatment of disorders mediated by an excess of substance p
JP2005502680A5 (pt)
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
MY139344A (en) 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
RU2002125495A (ru) Гидроксифенил-пиперидин-4-илиден-метил-бензамидные производные для лечения боли
HUP0002272A2 (hu) Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
YU75603A (sh) Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
ATE224893T1 (de) Pyrazolopyridinverbindung und seine pharmazeutische verwendung
TW200726769A (en) Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates
JP2002540146A5 (pt)
AP9901473A0 (en) Use of benzopyranols to treat neurological disorders.
IL108730A0 (en) Heterocyclic compounds, their preparation and pharmaceutical compositions containing them
JP2005525301A (ja) 神経成長刺激、瘢痕組織形成阻害および／または二次損傷低減のための、ｒｈｏ−キナーゼ阻害剤の利用
IT1223395B (it) Composti ad attivita' cardiovascolare
MXPA01009384A (es) Composiciones farmaceuticas que comprenden un derivado de pirimidina y ciclodextrina.
EP0398171A3 (de) Verwendung von Imidazodiazepinen bei der Behandlung von neurologischen Symptomen, welche mit zirkulatorischen Störungen des Gehirns assoziiert sind
ECSP972256A (es) Nuevo tratamiento y/o profilaxis de enfermedades degenerativas

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.